FHU PROMICE AP-HP, Saint Louis and DMU Parabol, Critical Care Medicine and Burn Unit, AP-HP, Department of Anesthesiology, Université Paris Cité, 75010 Paris, France.
INSERM, UMR 942, MASCOT, Cardiovascular Marker in Stress Condition, Université Paris Cité, 75010 Paris, France.
Int J Mol Sci. 2022 Mar 14;23(6):3124. doi: 10.3390/ijms23063124.
Galectin-3 (Gal-3) is a 30KDa lectin implicated in multiple pathophysiology pathways including renal damage and fibrosis. Gal-3 binds β-galactoside through its carbohydrate-recognition domain. From intra-cellular to extra-cellular localization, Gal-3 has multiple roles including transduction signal pathway, cell-to-cell adhesion, cell to extracellular matrix adhesion, and immunological chemoattractant protein. Moreover, Gal-3 has also been linked to kidney disease in both preclinical models and clinical studies. Gal-3 inhibition appears to improve renal disease in several pathological conditions, thus justifying the development of multiple drug inhibitors. This review aims to summarize the latest literature regarding Gal-3 in renal pathophysiology, from its role as a biomarker to its potential as a therapeutic agent.
半乳糖凝集素-3(Gal-3)是一种 30kDa 的凝集素,涉及多种病理生理学途径,包括肾损伤和纤维化。Gal-3 通过其碳水化合物识别域与β-半乳糖苷结合。Gal-3 从细胞内到细胞外定位,具有多种作用,包括转导信号通路、细胞间黏附、细胞与细胞外基质黏附以及免疫化学趋化蛋白。此外,Gal-3 还与临床前模型和临床研究中的肾脏疾病有关。Gal-3 抑制似乎可改善多种病理条件下的肾脏疾病,因此有理由开发多种药物抑制剂。本综述旨在总结有关 Gal-3 在肾脏病理生理学中的最新文献,从其作为生物标志物的作用到作为治疗剂的潜力。